查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128593

子宮肌瘤治療藥物的市場規模、佔有率、成長率和全球產業分析，區域趨勢，以及 2026 年至 2034 年的預測。

Uterine Fibroid Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

子宮肌瘤治療市場的成長要素

2025年全球子宮肌瘤治療市場規模為29.7億美元，預計2026年將成長至33.8億美元，2034年將達到90億美元，預測期內複合年成長率（CAGR）為13.04%。北美地區在全球市場中佔主導地位，預計2025年將佔45.56%的市場佔有率，這主要得益於該地區較高的診斷率、先進的醫療基礎設施、積極的醫藥投資以及創新藥物療法的廣泛應用。

子宮肌瘤（也稱為平滑肌瘤）是生長在子宮內或子宮表面的非癌性腫瘤。雖然許多女性沒有症狀，但有些女性可能會出現月經量過多、骨盆腔疼痛、貧血、不孕症和泌尿道功能障礙等症狀。肥胖率上升、久坐的生活方式、荷爾蒙失衡、閉經延遲以及代謝紊亂的增加，導致全球子宮肌瘤的發生率顯著上升。因此，人們對能夠維持生育能力並提高生活品質的有效非手術治療方法的需求日益成長。基因治療、荷爾蒙調節和標靶藥物研發等領域的持續研究，正進一步加速市場成長。

市場促進因素

子宮肌瘤治療市場的主要促進因素之一是子宮肌瘤對育齡女性日益沉重的負擔。已發表的醫學研究表明，約70%的白人女性和80%的非裔美國女性在其一生中的某個階段會患上子宮肌瘤，其中約30%的患者會出現需要治療的嚴重症狀。

與手術治療相比，保留子宮療法的日益普及推動了藥物治療的需求成長。現代藥物療法能夠有效控制出血過多、縮小肌瘤、緩解骨盆腔疼痛並改善懷孕結果。女性對子宮肌瘤的認知不斷提高、診斷技術的進步以及醫療服務覆蓋範圍的擴大，都持續推動全球對子宮肌瘤治療的需求。

市場趨勢

製藥公司之間的策略聯盟正成為塑造全球子宮肌瘤治療市場的重要趨勢。各公司正日益加強合作，以加速臨床開發、促進商業化並擴大其地域覆蓋範圍。

合作研究已在新一代促性腺激素釋放激素受體拮抗劑、選擇性黃體素受體調變器和新型荷爾蒙療法取得了顯著進展。對個人化醫療和基因療法的投入增加有望創造長期成長機會。

市場限制因素

儘管成長前景強勁，但治療相關的副作用仍是市場限制因素。荷爾蒙療法常用於治療子宮肌瘤，但會導致骨骼密度下降、潮熱、心血管併發症和其他副作用，進而影響患者的長期治療順從性。

此外，監管機構要求在批准與女性健康相關的療法之前，提交詳盡的長期安全性數據。嚴格的監管要求增加了研發成本，延長了產品開發週期，並延緩了創新療法的商業化。

市場區隔

按藥物分類

預計到2026年，GnRH促效劑將引領全球市場，佔54.18%的市佔率。這些療法目前被廣泛應用，因為它們已被證實能快速縮小子宮肌瘤並抑制月經，無論是在術前還是長期症狀管理方面。

另一方面，在臨床研發管線不斷擴大、監管部門獲得批准以及創新口服療法上市的推動下，GnRH拮抗劑領域預計將在預測期內實現顯著成長。

按類型

預計到2026年，肌壁間子宮肌瘤市佔率將達到53.40%。肌壁間子宮肌瘤是子宮肌瘤中最常見的類型，常伴隨嚴重出血、骨盆腔疼痛、不孕和貧血等症狀，因此對藥物治療的需求量很大。

此外，由於診斷和治療率的提高，預計粘膜下纖維瘤部分也將呈現強勁成長。

透過行政途徑

預計到 2026 年，注射劑市場將佔主導地位，市場佔有率達到 72.72%，這主要得益於緩釋注射劑的高效性以及醫生對長效療法的日益青睞。

另一方面，由於患者用藥便利性提高、治療依從性增強以及新批准的口服藥物供應增加，預計口服藥物市場將快速成長。

用途別

預計到2026年，子宮肌瘤縮小療法將以56.42%的市佔率引領市場。能夠縮小子宮肌瘤的藥物療法正獲得醫生和患者的大力支持，因為它們既能長期緩解症狀，又能減少侵入性手術的需求。

此外，鑑於人們對基於症狀的治療的認知不斷提高，疼痛管理療法預計也將穩步成長。

透過分銷管道

由於零售藥局和藥局覆蓋範圍廣、處方藥取得便捷，它們在全球市場佔主導地位。預計到2025年，這一細分市場將占到43.10%的市場佔有率，並持續受益於不斷擴大的藥房網路和改善的門診服務。

預計在預測期內，醫院藥局將穩定成長，這主要得益於因子宮肌瘤症狀而住院的患者人數不斷增加。

區域趨勢

預計北美市場規模將在2025年達到13.5億美元，2026年達到15.4億美元，繼續維持在主導地位。光是美國市場預計在2026年就將達到14.6億美元，這主要得益於臨床試驗活動的活性化、有利的報銷政策以及持續不斷的新產品上市。

2025 年歐洲市場規模達到 7.7 億美元，預計到 2026 年將成長至 8.7 億美元，這得益於人們意識的提高、健全的公共醫療保健體係以及先進口腔療法的日益普及。

預計到 2025 年，亞太地區的市場規模將達到 6.1 億美元，到 2026 年將增至 7 億美元，這主要得益於中國、印度、日本和其他新興經濟體的意識提高、醫療基礎設施的擴張以及診斷率的上升。

預計拉丁美洲市場規模將在 2025 年達到 1.3 億美元，在 2026 年達到 1.5 億美元。同時，在生殖保健服務改善和創新療法普及的推動下，中東和非洲市場預計將在 2025 年達到 1.1 億美元，在 2026 年達到 1.2 億美元。

近期行業發展包括監管部門的批准、許可協議、商業化夥伴關係以及創新 GnRH 拮抗劑和下一代口服療法的研發管線推進，旨在改善子宮肌瘤的長期治療。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家和地區的監管情景
  • 管道分析：按主要公司分類
  • 2025年主要國家/地區子宮肌瘤流行病學
  • 產業重大發展動態（合併、收購、合作、新產品發布等）

第5章：2021-2034年全球子宮肌瘤治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • GnRH拮抗劑
    • GnRH促效劑
    • 其他
  • 市場分析、洞察與預測：按類型
    • 肌壁內肌瘤
    • 黏膜下纖維瘤
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按應用領域分類
    • 減少
    • 疼痛管理
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美子宮肌瘤治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲子宮肌瘤治療市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區子宮肌瘤治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年拉丁美洲子宮肌瘤治療市場分析、洞察與預測

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲子宮肌瘤治療市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • AbbVie Inc.
    • Sumitomo Pharma Co., Ltd.
    • Pfizer Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • ObsEva SA
    • Neurocrine Biosciences, Inc.
    • TiumBio Co., Ltd.
    • Daewon Pharmaceutical Co., Ltd.
Product Code: FBI114341

Growth Factors of uterine fibroid drugs Market

The global uterine fibroid drugs market was valued at USD 2.97 billion in 2025 and is projected to grow from USD 3.38 billion in 2026 to USD 9.00 billion by 2034, registering a CAGR of 13.04% during the forecast period. North America dominated the global market with a 45.56% market share in 2025, supported by a high diagnosis rate, advanced healthcare infrastructure, strong pharmaceutical investments, and the increasing availability of innovative drug therapies.

Uterine fibroids, also known as leiomyomas, are non-cancerous tumors that develop within or on the uterus. While many women remain asymptomatic, others experience heavy menstrual bleeding, pelvic pain, anemia, infertility, and urinary complications. Rising prevalence of obesity, sedentary lifestyles, hormonal disorders, delayed menopause, and metabolic diseases has significantly increased the incidence of uterine fibroids worldwide. Consequently, there is growing demand for effective non-surgical therapies that preserve fertility and improve quality of life. Continuous research into gene therapy, hormone modulation, and targeted drug development is further accelerating market growth.

Market Drivers

One of the primary drivers of the uterine fibroid drugs market is the growing burden of uterine fibroids among women of reproductive age. According to published medical studies, uterine fibroids affect nearly 70% of white women and 80% of women of African ancestry during their lifetime, while approximately 30% develop severe symptoms requiring medical treatment.

The increasing preference for uterus-preserving therapies over surgical procedures has accelerated demand for pharmaceutical treatments. Modern drug therapies effectively reduce excessive bleeding, shrink fibroids, relieve pelvic pain, and improve fertility outcomes. Growing awareness among women, improved diagnosis, and expanding healthcare access continue to strengthen the global demand for uterine fibroid medications.

Market Trends

Strategic collaborations among pharmaceutical companies have emerged as a major trend shaping the global uterine fibroid drugs market. Companies are increasingly partnering to accelerate clinical development, strengthen commercialization, and expand geographic reach.

Collaborative research initiatives have also resulted in significant progress in next-generation GnRH receptor antagonists, selective progesterone receptor modulators, and novel hormonal therapies. Increasing investments in personalized medicine and gene-based therapies are expected to create substantial long-term growth opportunities.

Market Restraints

Despite robust growth prospects, treatment-related adverse effects remain a significant market restraint. Hormonal therapies commonly used for fibroid management may cause bone density loss, hot flashes, cardiovascular complications, and other side effects, limiting long-term treatment adherence.

Regulatory agencies also require extensive long-term safety data before approving women's health therapies. Strict regulatory requirements increase research costs, prolong product development timelines, and delay commercialization of innovative therapies.

Market Segmentation

By Drug Class

The GnRH agonists segment is projected to dominate the global market with a 54.18% market share in 2026. These therapies remain widely prescribed due to their proven effectiveness in rapidly shrinking fibroids and controlling heavy menstrual bleeding before surgery or as long-term symptom management.

Meanwhile, the GnRH antagonists segment is expected to witness significant growth during the forecast period, supported by expanding clinical pipelines, regulatory approvals, and the launch of innovative oral therapies.

By Type

The intramural fibroids segment is anticipated to account for 53.40% of the market in 2026. As the most common type of uterine fibroid, intramural fibroids are frequently associated with severe bleeding, pelvic pain, fertility complications, and anemia, creating substantial demand for pharmacological treatment.

The submucosal fibroids segment is also expected to register strong growth due to increasing diagnosis and treatment rates.

By Route of Administration

The parenteral segment is projected to dominate the market with a 72.72% share in 2026, driven by the high efficacy of injectable sustained-release formulations and increasing physician preference for long-acting therapies.

However, the oral segment is expected to witness rapid growth owing to improved patient convenience, better treatment adherence, and increasing availability of newly approved oral medications.

By Application

The shrinkage segment is expected to lead the market with a 56.42% share in 2026. Drug therapies capable of reducing fibroid size provide long-term symptom relief while lowering the need for invasive surgical procedures, making them highly preferred among both physicians and patients.

Pain management therapies are also expected to grow steadily as awareness regarding symptom-based treatment continues to improve.

By Distribution Channel

Retail pharmacies and drug stores dominated the global market due to their widespread accessibility and availability of prescription medications. The segment accounted for 43.10% of the market in 2025 and continues to benefit from expanding pharmacy networks and improved outpatient treatment services.

Hospital pharmacies are expected to record healthy growth during the forecast period due to increasing hospital admissions for symptomatic uterine fibroids.

Regional Insights

North America generated USD 1.35 billion in 2025 and is projected to reach USD 1.54 billion in 2026, maintaining its leadership position in the global market. The U.S. market alone is estimated to reach USD 1.46 billion in 2026, driven by increasing clinical trial activity, favorable reimbursement policies, and continuous product launches.

Europe accounted for USD 0.77 billion in 2025 and is expected to grow to USD 0.87 billion in 2026, supported by rising awareness, strong public healthcare programs, and increasing adoption of advanced oral therapies.

Asia Pacific reached USD 0.61 billion in 2025 and is forecast to increase to USD 0.70 billion in 2026, fueled by growing awareness, expanding healthcare infrastructure, and rising diagnosis rates across China, India, Japan, and other emerging economies.

Latin America generated USD 0.13 billion in 2025 and is projected to reach USD 0.15 billion in 2026, while the Middle East & Africa market stood at USD 0.11 billion in 2025 and is expected to reach USD 0.12 billion in 2026, supported by improving reproductive healthcare services and increasing access to innovative therapies.

Competitive Landscape

The global uterine fibroid drugs market is semi-consolidated, with leading companies focusing on strategic collaborations, product approvals, clinical research, and geographic expansion to strengthen their market position.

Major market participants include AbbVie Inc., Pfizer Inc., Neurocrine Biosciences, Inc., Sumitomo Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., ObsEva SA, TiumBio Co., Ltd., and Daewon Pharmaceutical Co., Ltd.

Recent industry developments include regulatory approvals, licensing agreements, commercialization partnerships, and pipeline advancements involving innovative GnRH antagonists and next-generation oral therapies designed to improve long-term management of uterine fibroids.

Conclusion

The global uterine fibroid drugs market is poised for strong expansion, growing from USD 2.97 billion in 2025 to USD 3.38 billion in 2026, and reaching USD 9.00 billion by 2034. Rising prevalence of uterine fibroids, increasing demand for fertility-preserving medical treatments, expanding pharmaceutical research, and continuous innovation in hormonal therapies are expected to drive sustained market growth. Although treatment-related adverse effects and stringent regulatory requirements remain key challenges, ongoing clinical advancements and strategic collaborations among leading pharmaceutical companies are expected to create significant opportunities for the global uterine fibroid drugs market over the coming decade.

Segmentation By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Region

By Drug Class * GnRH Antagonists

  • GnRH Agonists
  • Others

By Type * Intramural Fibroid

  • Submucosal Fibroid
  • Others

By Route of Administration * Oral

  • Parenteral

By Application * Shrinkage

  • Pain Management
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography * North America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Type, Route of Administration, Application, Distribution Channel, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemology of Uterine Fibroids, By Key Countries/ Regions, 2025
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. GnRH Antagonists
    • 5.1.2. GnRH Agonists
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Intramural Fibroid
    • 5.2.2. Submucosal Fibroid
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Application
    • 5.4.1. Shrinkage
    • 5.4.2. Pain Management
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies & Drug Stores
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. GnRH Antagonists
    • 6.1.2. GnRH Agonists
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Intramural Fibroid
    • 6.2.2. Submucosal Fibroid
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Application
    • 6.4.1. Shrinkage
    • 6.4.2. Pain Management
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies & Drug Stores
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. GnRH Antagonists
    • 7.1.2. GnRH Agonists
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Intramural Fibroid
    • 7.2.2. Submucosal Fibroid
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Application
    • 7.4.1. Shrinkage
    • 7.4.2. Pain Management
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies & Drug Stores
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. GnRH Antagonists
    • 8.1.2. GnRH Agonists
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Intramural Fibroid
    • 8.2.2. Submucosal Fibroid
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Application
    • 8.4.1. Shrinkage
    • 8.4.2. Pain Management
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies & Drug Stores
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. GnRH Antagonists
    • 9.1.2. GnRH Agonists
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Intramural Fibroid
    • 9.2.2. Submucosal Fibroid
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Application
    • 9.4.1. Shrinkage
    • 9.4.2. Pain Management
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies & Drug Stores
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. GnRH Antagonists
    • 10.1.2. GnRH Agonists
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Intramural Fibroid
    • 10.2.2. Submucosal Fibroid
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Application
    • 10.4.1. Shrinkage
    • 10.4.2. Pain Management
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies & Drug Stores
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc.
    • 11.2.2. Sumitomo Pharma Co., Ltd.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Kissei Pharmaceutical Co., Ltd.
    • 11.2.5. ObsEva SA
    • 11.2.6. Neurocrine Biosciences, Inc.
    • 11.2.7. TiumBio Co., Ltd.
    • 11.2.8. Daewon Pharmaceutical Co., Ltd.

List of Tables

  • Table 1: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 3: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 4: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 5: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 09: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 10: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 11: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 15: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 16: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 17: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 21: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 22: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 27: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 28: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 29: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 33: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 34: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 35: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Uterine Fibroid Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Uterine Fibroid Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Uterine Fibroid Drugs Market Value Share (%), by Application, 2025 & 2034
  • Figure 6: Global Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Uterine Fibroid Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 11: North America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 12: North America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 13: North America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 14: North America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 15: North America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 16: North America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Uterine Fibroid Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Uterine Fibroid Drugs Market Value Share (%), by Country, 2025
  • Figure 20: Europe Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 23: Europe Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 24: Europe Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 25: Europe Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 26: Europe Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 27: Europe Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 28: Europe Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 35: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 36: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 37: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 38: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 39: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 40: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 47: Latin America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 48: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 49: Latin America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 50: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 51: Latin America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 52: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 59: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 60: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 61: Middle East & Africaa Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 62: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 63: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 64: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Uterine Fibroid Drugs Market Share (%), by Company, 2025